KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.97

Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT).

Simon Couillard, Nayia Petousi, Sanjay Ramakrishnan, Renzo Valle, Amelie Tétu, Samuel Lemaire-Paquette, Changming Xia, Steve Poirier, Olivier Ledanois, Rebecca Gall, Andréanne Côté, Nermin Diab, Philippe Lachapelle, Ian D Pavord

Ann Allergy Asthma Immunol 137(1) 116-123.e26

PMID41967704
PMCID-
DOI10.1016/j.anai.2026.03.028
发表日期2026-04-12
入排依据:方案论文未报告临床试验结果。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

INTRODUCTION: Asthma is a prevalent chronic respiratory disease in which up to 44% of patients require systemic corticosteroids annually. Many have active type-2 inflammation, characterized by elevated blood eosinophils and/or fractional exhaled nitric oxide (FeNO), type-2 biomarkers that predict asthma attacks and lung function decline. Biologics such as the interleukin-4/13 targeting dupilumab have exhibited efficacy in patients with moderate-to-severe asthma and raised type-2 biomarkers, yet their role in inducing clinical remission earlier in the disease course remains untested. We speculate that dupilumab intervention can induce clinical remission in adults with at-risk type-2 inflammatory asthma. METHODS AND ANALYSIS: We report the protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled, phase 3b superiority trial (HOTHOT). Adults with established asthma, blood eosinophils of at greater than or equal to 0.3 × 109/L, FeNO greater than or equal to 35 parts per billion, and at least 1 severe asthma attack in the past 24 months and maintained on at least medium-dose inhaled corticosteroids (ICS) will be eligible. A total of 150 participants will be randomized 1:1 to fortnightly dupilumab or volume-matched placebo for more than 56 weeks. Background ICS therapy will be adjusted every 3 months on the basis of symptoms and spirometry, blinded to biomarker data. The primary end point is the win ratio on the basis of remission criteria at week 56, hierarchically comparing absence and number of severe attacks, preserved forced expiratory volume in 1 second, maintenance on medium-dose ICS or less, and 5-item asthma control questionnaire score less than 1.5. Secondary outcomes include the annualized severe attack rate, remission win ratio in the medium-dose ICS subgroup, change in forced expiratory volume in 1 second, and a binary remission end point. ETHICS AND DISSEMINATION: The study is approved by the Research Ethics Committee of the Integrated University Health and Social Services Centre de l'Estrie- Centre Hospitalier Universitaire de Sherbrooke (MP-31-2026-6116). The protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2025 guidelines. Results will be disseminated at international meetings and in peer-reviewed journals in accordance with the Consolidated Standards of Reporting Trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT07309614.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。